Information Provided By: 
Fly News Breaks for February 25, 2019
BLUE
Feb 25, 2019 | 09:02 EDT
SunTrust analyst Edward Nash lowered his price target on Bluebird Bio to $184 to reflect his updated expectations of E.U. LentiGlobin approval and bookings coming in 2020, rather 2019, along with a shallower penetration curve of the treatment in the U.S. The analyst is also keeping his Buy rating on the shares and sees Bluebird Bio as "best positioned to transition gene therapy from a scientific endeavor to a successful commercial proposition" given its "five potentially curative products in the clinic".
News For BLUE From the Last 2 Days
There are no results for your query BLUE
